Бронхолегочные инфекции: сопоставление данных микробиологического исследования мокроты в ретроспективе (1984 и 2004 гг.) и оптимизация схем антибактериальной терапии пульмонологических больных
Диссертация
В большинстве случаев выбор исходного антибактериального препарата осуществляется эмпирическим путем на основании характерной клинической картины заболевания, данных анамнеза и сопутствующей патологии (ХОБЛ, хроническая сердечная недостаточность, сахарный диабет, онкологические заболевания). Для принятия оптимальных решений необходимо знание этиологической структуры наиболее часто встречающихся… Читать ещё >
Список литературы
- Авдеев С.Н. с соавт. Бактериальная инфекция у больных ХОБЛ. // Клин микробиол антимикроб химиотер. — 2005. — т7. — № 3. — с. 245−254.
- Бартлетт Джон Дж. Инфекции дыхательных путей. // Бином-Москва. -2000. с. 9−52.
- Вишнякова Л.А. Бактериальный воспалительный процесс при различных острых и хронических заболеваниях легких. Механизмы воспаления бронхов и легких и противовоспалительная терапия.// СПб.:Нормед. — 1998. с. 67−83.
- Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких Пер. с англ. под ред. Чучалина А. Г. // М.: Издательский дом «Атмосфера». — 2007.
- Дворецкий Л.И. Респираторные фторхинолоны в лечении обострений хронического бронхита.//СопзШит medicum. 2007. -т7. -№ 4. — с. 284−289.
- Дворецкий Л.И., Данилина В. А. Клиническое значение резистентных пневмококков. Инфекции и антимикробная терапия. 2004. — тб. — № 4. — с.126−133.
- Европейское руководство по клинической оценке противоинфекционных лекарственных средств //Пер. с англ. Смоленск. -1996. с. 82−109.
- Зубков М.Н. Сбор, транспортировка биологического материала и трактовка результатов микробиологических исследований. //Клин микробиол и антимикроб химиотер. 2004. — тб. — № 2. — с. 143−154.
- Зубков М. Н Этиология и патогенез внеболышчных пневмоний у взрослых.//Пульмонология. 2005. —№ 5. — с.53−60.
- Мизерницкий Ю.Л. Место современных макролидов в терапии пневмоний // Consilium medicum: болезни органов дыхания. 2008. — с. 19−22.
- Ноников В.Е., Константинова Т. Д., Ленкова Н. И., Аргеткина И. Н. Фармакоэкономические аспекты антибактериальной терапии пневмоний //Инфекции и антимикробная терапия. — 1999. — т2. — с.44−46.
- Ноников В.Е. Атипичные пневмонии: второе рождение макролидов //Новый медицинский журнал. 1995. — № 1. — с.5−7.
- Ноников В.Е., Воробьева М. Г. Атипичные пневмонии (микоплазмоз, хламидиоз, легионеллез) диагностика и лечение. // Справочник поликлинического врача. — 2006. — № 10. с. 6−11.
- Падейская Е.Н., Яковлев В. П. Антимикробные препараты группы фторхинолонов в клинической практике// «Логата», Москва. 1998. — с.126−128.
- Сахарчук И.И., Ильницкий Р. И., Дудка П. Ф. Воспалительные заболевания бронхов: дифференциальная диагностика и лечение.// Киев, Книга плюс. — 2005. -с.87−190.
- Сидоренко С.В. Резистентность микроорганизмов и антибактериальная терапия.// РМЖ. 1998. -т.6. -№ 11. — с. 717−725.
- Сидоренко С.В., Яковлев С. В. Бета-лактамные антибиотики. //РМЖ. — 199. —т.5. —№ 21. — с.1367−1382.
- Синопальников А.И., А.Г.Романовских Инфекционное обострение хронической обструктивной болезни легких. // Пульмонология. — 2006. — т8. — № 1.
- Страчу некий Л. С., Козлов С. Н. «Современная антимикробная химиотерапия». Руководство для врачей. // Москва: Боргес. 2002. — с.ЗО.
- Строганов В.П. Феномен резистентности.// Медицина для всех. — 1998. -т.5.-№ 11.-с.20−21.
- Тартаковский И.С. Современные подходы к диагностике атипичных пневмоний. // Клин. Микробиология и антимикробная химиотерапия. 2000. -том 2. -№ 1. -с.60−68.
- Утешев Д. Б Диагностика и лечение инфекционных заболеваний нижних дыхательных путей.//Русский Медицинский Журнал. 2008. — том 16. — № 2. — с.74−77
- Чучалин А.Г., Синопальников А. И., Страчунский JI.C. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике.// М.: ООО «Издательский дом «М-Вести». 2006.
- Чучалин А. Г. Синопальников А.И. Козлов Р. С. и др Инфекционное обострение ХОБЛ: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. //Москва. 2005.
- Чучалин А. Г. Синопальников А.И. Чернеховская Н. Е. Пневмония. //Москва. 2002. — с.9−49.
- Almirall J, Bolibar I, Vidal J, et al Epidemiology of community-acquired pneumonia in adults: a population-based study.//Eur. Respir J. 2000. — 15. -P.757−763.
- Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.// Ann Intern Med. 1987. -№ 106. — P.196−204.
- Aspa J, Rajas O, Rodriguez de Castro F et al. Drug-Resistant Pneumococcal Pneumonia: Clinical Relevance and Related Factors. //Clinical Inf Dis. — 2004. -№ 38. — P.787−789.
- Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary diseaseia summary and appraisal of published evidence. //Ann Intern Med. -2001. -№ 134. P.600−20.
- Baldwin DR, Andrews JM, Wise R, Honeybourne D. Bronchoalveolar distribution of cefuroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens. // J Antimicrob Chemother. —1992. —"№ 30. — P.377 -385
- Ball P. Epidemiology and treatmemt of chronic bronchitis and its exacerbations. //Chest. -1995. -№ 108. -P.43S-52S.
- Bartlett JG, Mundy L. Community-acquired pneumonia.//N Eng J Med. -1995.-№ 333.-P.1618−24.
- Bartlet JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases of America. //Clin Infect Dis. -1998. -№ 26. -P.811−838.
- Bartlett John G, Scott F. Dowell, Lionel A. Mandell, Thomas M. File, Jr., Daniel M. Musher, Michael J. Fine. Practice Guidelines for the Management of
- Community-Acquired Pneumonia in Adults. (Guidelines from the Infectious Diseases Society of America). // Clin Mectious Diseases. -2000. -№ 31. -P.347−382.
- Blanqer J, Blanqer R, Borrs. R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. //Thorax. —1991. — № 46. — P.508−511.
- Blasi F., Tarsia P. Value of short-course antimicrobial therapy in Community-Acquired Pneumonia. //Inf J Antimicrob Agents. 2005. — № 26. — P. S148-S155.
- British Thoracic Society and Public Heath Laboratory Service. Community-acquired pneumonia in adults in the British hospitals in 1982−1983: a survey of aetiology, mortality, prognostic factors and autcome.//Q J Med. -1987. № 239. -P. 195−220.
- British Thoracic Society. BTS guidelines for the management of community acquired pneumonia in adults. //Thorax. — 2001. — № 56. — Suppl. TV. P. 1−64.
- Canut A, Martin-Herrero JE, Labora A, et ai What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model.// J Antimicr Chemother. — 2007. -№ 60. — P.605−612.
- Chen DK, McGeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. //N Engl J Med. 1999. — Vol 341. — № 13. -P.233−239.
- Connors AF, Dawson NV, Thomas C et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease.// Am J Respir Crit Care Med. 1996. -№ 154. -P.959.
- Davies, B. I., and F. P. V. Maesen. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in vitro activity.//! Antimicrob. Chemother. 1999. -№ 43. -P.83−90.
- Doern GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus Pneumoniae in Unated States: have we begun to tum the comer on resistance to certain antimicrobial classes// Clin Infect Dis. — 2005. — № 41. — P. 139−148.
- Dunbar, LM, Wunderink, RG, Habib, MR, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.// Clin Infect Dis. 2003. — № 37. -P.752−760.
- Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H, Infective exacerbations of chronic bronchitis: relation between bacteriologic aetiology and lung function.//Chest. -1998. -№ 113. -P. 1542−1548.
- Ethan A. Halm, M.D., M.P.H., and Alvin S. Teirstein, M.D. Management of Community-Acquired Pneumonia. //N Engl J Med, 2002: Vol 347, 25:2039−2045
- Fang GD, Fine M, Orloff J, et bal. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. //Medicine (Baltimore). — 1990. — № 69. — P.307−316.
- Francis JS, Doherty MC, Lopatin U et al. Severe Community-onset Pneumonia in healthy adults caused by MRSA carrying the Panton-Valentine leukocidin genes.//Clin Infect Dis. -2005. -№ 40. -P.100−107.
- Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalizedelderly patients with pneumonia. //Arch Intern Med. 1999. — № 159. — P.2562−2572.
- Goh SK, Johan A, Cheong TH et al. A prospective study of infections with atypical pneumonia organisms in acute exacerbations of chronic bronchitis. //Ann Acad Med Singapore. -1999. № 28. -P.476−480.
- Henriques B, Kalin M, Ortqist A et al. Molecular epidemiology of Streptococcus pneumonia causing invasive disease in 5 countries.// J Infect Dis. -2000,-№ 182.-P.833−839.
- Niederman MS, McCombs JI, Under AN. The cost of treating community-acquired pneumonia. II Clin Ther. 1998. -№ 20. -P.820−837.
- Hirschmann Jan V., MD. Do Bacteria Cause Exacerbations of COPD? //Chest. -2000. -№ 118. P. 193−203.
- Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community—acquired respiratory tract infections. // J Antimicrob Chemother. — 2002. № 50(Suppl SI). -P.49−59.
- Huchon G, Woodhead M and the ERS Task Force. Guidelines for Management of adult community-acquired lower respirator}' tract infectious. //Eur Respir J. -1998.-№ 11. — P.986−991.
- Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children.// Infection. 2001. — № 29. -P.251 -256.
- Kauppinen MT, Saikku P, Kujala P, et al. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. //Thorax. 1996. — № 51. — P. 185−189.
- Kuhnke A., H.Lode. Fluoroqunolones and lower respiratory tract infections.// Eur Respir Mon. 2004. — № 28. — P.94−112.
- Langan, C., B. Clecner, C. M. Cazzola, C. Brambilla, C. Holmes, and H. Staley. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. //Int. J. Clin. Pract. 1998. — № 52. -P.289−297.
- Langan, C. E., R. Cranfleld, S. Breisch, and R. Pettit. Randomized, doubleblind study of grepafloxacin versus amoxycllin in patients with acute bacterial exacerbations of chronic bronchitis.//J. Antimicrob. Chemother. —1997. — № 40. — P. 63−72.
- Lindenauer PK, Pekow P, Gao S, et al quality of care for patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. // Ann Intern Med. 2006. — № 144. — P.894−903.
- Lode H, Allewent M, Balk S et al. A prediction model for bacterial etiology in acute exacerbation of COPD. // Infection. 2007. — № 35. — P. 143−149.
- Macfarlane JT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. //Lancet. — 1993.-№ 341.-P.511−514.
- Madison JM, Irwin RS. Chronic obstructive pulmonary disease. //Lancet. -1998.-№ 352.-P.467−473
- Maria G. Di, L. Spicuzza, R. Polosa. Antibiotics and new guidelines for the treatment of lower respiratory tract infections.// Eur Respir Mon. 2004. — № 28. -P.175−188.
- McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. //Chest. 2001. -№ 119. — P. 1190−1209
- Meehan TP, Fine MJ, Kramholz HM et al. Quality of care, process, and outcomes in elderly patients with, pneumonia. //JAMA. 1997. — № 278. — P.2080−2084.
- Miravitlles M. Exacerbation chronic obstructive pulmonary disease: when are bacteria important. //Eur Respir J. 2002. — Suppl.36. — P.9s-19s.
- Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbation of COPD.// Chest. -1999. № 116. P.40−46.
- Moine Pierre, M.D., Jean-Baptiste Vercken, M.D., Sylvie Chevret, M.D., et all. Severe Community-acquired Pneumonia: Etiology, Epidemiology, and Prognosis Factors.// Chest. -1994. -№ 105. -P. 1487−1495.
- Monso E. Ruiz J, Rosell A. et al. Bacterial infection in clironic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. //Am J Respir Crir Care Med. 1995. — № 152. — P.1316−1320.
- Mundy LM, Auwaerter PG, Oldach. D, et al. Community-acquired pneumonia. Impact of immune status. //Am J Respir Crit Care Med. 1995. — № 152. — P. 13 091 315.
- Murphy TF, Sethy S. Bacterial infection in chronic obstructive pulmonary disease.// Am Rev Respir Dis. -1992. -№ 146. -P. 1067−1083.
- Niederman Michael S. Recent Advances in Community-Acquired Pneumonia: Inpatient and Outpatient. //Chest. -2007. -№ 131. P. 1205−1215.
- Niderman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. //An Rev Respir Dis. 1993. -№ 148. -P.1418−1426.
- Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. //Am J Respir Crit Care Med. 2001. — № 163. — P. 1730−1754.
- Puhan MA, Vollenweider D, et al. Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbation with antibiotics? A systematic review.// BMC Med. 2008. — № 6. — P.28.
- Ram FS, Rodrigues-Roisin R, Granados-Navarrete A et al. Antibiotics for exacerbation of chronic obstructive pulmonary disease. //Cochrane Database Syst Rev. 2006. — CD004403.
- Roede BM, Bindeis PJ, Brouwer HJ, et al. Antibiotics and steroid for exacerbation of COPD in primary care: compliance with Dutch guidelines. // Br J Gen Pract. 2006. — № 56. — P.662−665.
- A. de Roux, S. Ewig, E. Garsia, M.A.Marcos, J. Mensa, et al. Mixed community-acquired pneumonia in hospitalised patients. //Eur Res J. — 2006. — Vol 27,№ 4. — P.795−800.
- Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. //Am J Respir Crit Care Med. 1999.-№ 160. -P.397−405.
- Russi E. W., Zurich- Ph. Leuenberger, Lausanne- O. Br/jndli, Wald- J. G. Frey, Montana. Management of chronic obstructive pulmonary disease: the Swiss guidelines. II Swiss Med WKLY. 2002. — № 132. — P.67−78.
- Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis.//JAMA. 1995. — № 273. -P.957—960.
- Sayiner A, Okyay N, Unsal L Infective Exacerbations of COPD. //Chest. -1999.-№ 115.-P.1481.
- Seemungal T.A., Donaldson G.C., Bhowmik A, et al. Time course and recovery of exacerbations in patients of chronic obstructive pulmonary disease. //Am J Respir Cril Care Med. 2000. -№ 161. -P.1608−1613.
- Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis.// Chest.-2000. -№ 117.-P.380S-385S.
- Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management.// J Antimicrob Chemother. 1999. — № 43(Suppl A). — P.97−105.
- Sethi Sanjay and Timothy F. Murphy «Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Revie.// Clinical Microbiology Reviews.-2001.-Apr. Vol.14. -P.336−363.
- Sethi Sanjay, MD, Nancy Evans, R.N., Brydon J.B. Grant M.D., and Timothy F. Murphy M.D. New strains of bacteria and exacerbations of Chronic Obstructive Pulmonary Disease.// N Engl J Med. 200. — Vol. 347,№ 7. — P.465−471.
- Siempos II, Dimopoulos G, Korbila IP, et al Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis.// Eur Respir. -2007.-№ 29. P. 1127−1137.
- Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. //Ann Intern Med. -2001. -№ 134. P.595−599.
- Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbation chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. //Am JRespir Crir Care Med. 1998. -№ 157. -P.1498−1505.
- Spika JF, Facklam RR, Plikaytis BD, et al. Antimicrobial resistance of Streptococcus pneumonia in the United States, 1979−1987. //J Infect Dis. 1991. -№ 163.-P. 1273−1278.
- Stahl J.E., Barza M., DesJaidin J., et al. Effectof macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. //Arch Intern Med. 1999. — № 159. — P.2576−2580.
- Stockley Robert A., Christine O’Brien, Anita Pye and Susan L. Hill Relationship of Sputum Color to Nature and Outpatient Management of Acute Exacerbations of COPD// Chest. -2000. -№ 117. -P.1638−1645.
- Stoller James K. Acute Exacerbation of Chronic Obstructive Pulmonary Disease. //N Engl J Med. 2002. — Vol 346,№ 13. — P.988−994.
- Tristram, Stephen, Michael R. Jacobs, and Peter C. Appelbaum. Antimicrobial Resistance in Haemophilus influenzae. //Clin Micr Rev. — 2007. -Apr. -P.368−389.
- Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial Resistance in Haemophilus influenzae and Moraxella catarrhalis Respiratory Tract Isolates:
- Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. // Antimicrob Agents Chemother. 2003. -№ 47 (6). — P. 1875−1881.
- Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A, for the Toronto Invasive Bacterial Disease Network. Predicting antimicrobial assistance in invasive pneumococcal infections.// Clin Infect Dis. 2005. — № 40(9). — P. 1288−1297.
- Walstad RA. Concentrations of antibiotics in sputum. // Res Clin Forums. -1990.-№ 12.-P.87−94.
- Zervos M, Martinez FJ, et al. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial acute exacerbation of chronic bronchitis.// Int J Antimicrob Agents. 2007. — № 29. — P.56−61.
- Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumonia in the United States. // N Engl J Med. — 2000. — Vol 343. -P.1917−1924.
- Wilson R. Bacteria, antibiotics and COPD. //Eur Respir J. 2001. — № 17. -P.995−1007.
- Woodhead M. community-acquired pneumonia in Europe: causative pathogens and resistance patterns. //Eur Respir J. — 2002. — № 20(Suppl. 36). -P.20s-27s.
- Woodhead M., F. Blasi, S. Ewig, G. Huchon, M. Leven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, TJ.MVerheij. Guidelines for the management of adult lower respiratory tract infections. // Eur Respir J. 2005. — vol 26,№ 6. — P.1138−1169.